Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Executive Summary
Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?
You may also be interested in...
Actelion Follows Innovation into GP Markets
Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
Actelion Follows Innovation into GP Markets
Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership
Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.